102 related articles for article (PubMed ID: 16648510)
1. Changes in neurologic function tests may predict neurotoxicity caused by ixabepilone.
Lee JJ; Low JA; Croarkin E; Parks R; Berman AW; Mannan N; Steinberg SM; Swain SM
J Clin Oncol; 2006 May; 24(13):2084-91. PubMed ID: 16648510
[TBL] [Abstract][Full Text] [Related]
2. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer.
Low JA; Wedam SB; Lee JJ; Berman AW; Brufsky A; Yang SX; Poruchynsky MS; Steinberg SM; Mannan N; Fojo T; Swain SM
J Clin Oncol; 2005 Apr; 23(12):2726-34. PubMed ID: 15837987
[TBL] [Abstract][Full Text] [Related]
3. Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials.
Vahdat LT; Thomas ES; Roché HH; Hortobagyi GN; Sparano JA; Yelle L; Fornier MN; Martín M; Bunnell CA; Mukhopadhyay P; Peck RA; Perez EA
Support Care Cancer; 2012 Nov; 20(11):2661-8. PubMed ID: 22382588
[TBL] [Abstract][Full Text] [Related]
4. Ixabepilone: a novel microtubule inhibitor for the treatment of locally advanced or metastatic breast cancer.
Steinberg M
Clin Ther; 2008 Sep; 30(9):1590-617. PubMed ID: 18840366
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes.
Denduluri N; Low JA; Lee JJ; Berman AW; Walshe JM; Vatas U; Chow CK; Steinberg SM; Yang SX; Swain SM
J Clin Oncol; 2007 Aug; 25(23):3421-7. PubMed ID: 17606971
[TBL] [Abstract][Full Text] [Related]
6. Neurotoxicity as a prognostic factor in patients with metastatic breast cancer treated with ixabepilone as a first-line therapy.
Durando X; Dalenc F; Abrial C; Mouret-Reynier MA; Herviou P; Kwiatkowski F; Chollet P; Roche H; Thivat E
Oncology; 2015; 88(3):180-8. PubMed ID: 25472499
[TBL] [Abstract][Full Text] [Related]
7. Phase II randomized trial of weekly and every-3-week ixabepilone in metastatic breast cancer patients.
Smith JW; Vukelja S; Rabe A; Wentworth-Hartung N; Koutrelakos N; Shao SH; Whittaker T; Wang Y; Asmar L; McDowell DO; Mukhopadhyay P; O'Shaughnessy J
Breast Cancer Res Treat; 2013 Nov; 142(2):381-8. PubMed ID: 24166282
[TBL] [Abstract][Full Text] [Related]
8. Novel neurosensory testing in cancer patients treated with the epothilone B analog, ixabepilone.
Goel S; Goldberg GL; Kuo DY; Muggia F; Arezzo J; Mani S
Ann Oncol; 2008 Dec; 19(12):2048-52. PubMed ID: 18644829
[TBL] [Abstract][Full Text] [Related]
9. The optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancer.
Boehnke Michaud L
J Oncol Pharm Pract; 2009 Jun; 15(2):95-106. PubMed ID: 19171553
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas.
Aghajanian C; Burris HA; Jones S; Spriggs DR; Cohen MB; Peck R; Sabbatini P; Hensley ML; Greco FA; Dupont J; O'Connor OA
J Clin Oncol; 2007 Mar; 25(9):1082-8. PubMed ID: 17261851
[TBL] [Abstract][Full Text] [Related]
11. A multi-center phase II study of BMS-247550 (Ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxane.
Ajani JA; Safran H; Bokemeyer C; Shah MA; Lenz HJ; Van Cutsem E; Burris HA; Lebwohl D; Mullaney B
Invest New Drugs; 2006 Sep; 24(5):441-6. PubMed ID: 16586011
[TBL] [Abstract][Full Text] [Related]
12. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer.
Galsky MD; Small EJ; Oh WK; Chen I; Smith DC; Colevas AD; Martone L; Curley T; Delacruz A; Scher HI; Kelly WK
J Clin Oncol; 2005 Mar; 23(7):1439-46. PubMed ID: 15735119
[TBL] [Abstract][Full Text] [Related]
13. A double-blind, randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy.
Campone M; Berton-Rigaud D; Joly-Lobbedez F; Baurain JF; Rolland F; Stenzl A; Fabbro M; van Dijk M; Pinkert J; Schmelter T; de Bont N; Pautier P
Oncologist; 2013; 18(11):1190-1. PubMed ID: 24105751
[TBL] [Abstract][Full Text] [Related]
14. Features and risk factors of peripheral neuropathy during treatment with bortezomib for advanced multiple myeloma.
El-Cheikh J; Stoppa AM; Bouabdallah R; de Lavallade H; Coso D; de Collela JM; Auran-Schleinitz T; Gastaut JA; Blaise D; Mohty M
Clin Lymphoma Myeloma; 2008 Jun; 8(3):146-52. PubMed ID: 18650177
[TBL] [Abstract][Full Text] [Related]
15. Epothilones: a novel class of microtubule-stabilizing drugs for the treatment of cancer.
Trivedi M; Budihardjo I; Loureiro K; Reid TR; Ma JD
Future Oncol; 2008 Aug; 4(4):483-500. PubMed ID: 18684060
[TBL] [Abstract][Full Text] [Related]
16. Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer.
Baselga J; Zambetti M; Llombart-Cussac A; Manikhas G; Kubista E; Steger GG; Makhson A; Tjulandin S; Ludwig H; Verrill M; Ciruelos E; Egyhazi S; Xu LA; Zerba KE; Lee H; Clark E; Galbraith S
J Clin Oncol; 2009 Feb; 27(4):526-34. PubMed ID: 19075286
[TBL] [Abstract][Full Text] [Related]
17. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
Badros A; Goloubeva O; Dalal JS; Can I; Thompson J; Rapoport AP; Heyman M; Akpek G; Fenton RG
Cancer; 2007 Sep; 110(5):1042-9. PubMed ID: 17654660
[TBL] [Abstract][Full Text] [Related]
18. Nail disorders in a woman treated with ixabepilone for metastatic breast cancer.
Alimonti A; Nardoni C; Papaldo P; Ferretti G; Caleno MP; Carlini P; Fabi A; Rasio D; Vecchione A; Cognetti F
Anticancer Res; 2005; 25(5):3531-2. PubMed ID: 16101175
[TBL] [Abstract][Full Text] [Related]
19. Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens.
Ray-Coquard I; Biron P; Bachelot T; Guastalla JP; Catimel G; Merrouche Y; Droz JP; Chauvin F; Blay JY
Cancer; 1998 Jan; 82(1):134-40. PubMed ID: 9428489
[TBL] [Abstract][Full Text] [Related]
20. A Phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days.
Zhuang SH; Agrawal M; Edgerly M; Bakke S; Kotz H; Thambi P; Rutt A; Balis FM; Bates S; Fojo T
Cancer; 2005 May; 103(9):1932-8. PubMed ID: 15800893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
